MarketPulse

TLX101-Px

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix's Brain Cancer Imaging Drug Advances in Europe After MAA Acceptance

Telix Pharmaceuticals' glioma imaging candidate TLX101-Px gains European regulatory validation, entering 210-day review phase with potential market approval expected.
TLXradiopharmaceuticalsPET imaging
GlobeNewswire Inc.GlobeNewswire Inc.··Telix Pharmaceuticals Limited

Telix Resubmits FDA Application for Brain Cancer Imaging Drug Pixclara

Telix resubmits FDA application for Pixclara, a brain cancer imaging agent with Orphan Drug and Fast Track designations, addressing a regulatory Complete Response Letter.
TLXorphan drug designationradiopharmaceuticals